DMAC (DiaMedica Therapeutics) Moat Score: 3/10 (As of Jun. 24, 2026)


DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $6.38
! 1 Warning Sign
View Full Analysis

What is DiaMedica Therapeutics Moat Score?

DiaMedica Therapeutics DMAC +1.75% 31 Moat Score is 3 as of Jun. 24, 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,405 Biotechnology companies, DiaMedica Therapeutics ranks better than 75.52% on this metric.

DiaMedica Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

DiaMedica Therapeutics has No Moat: DiaMedica Therapeutics has potential in its R&D capabilities but lacks approved products, significant patents, or market share, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes DiaMedica Therapeutics might have No Moat - Very weak/transient advantages.

DiaMedica Therapeutics  (NAS:DMAC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

DiaMedica Therapeutics Moat Score Related Terms

DMAC vs BCYC, RZLT, ABEO: Moat Score Comparison

For the Biotechnology subindustry, DiaMedica Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DiaMedica Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's Moat Score falls into.


DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
DiaMedica Therapeutics (DMAC) has a Moat Score of 3 as of Jun. 24, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, DiaMedica Therapeutics ranks #344 out of 1405 companies in the Biotechnology industry, placing it in the top 24.5%.
Is DiaMedica Therapeutics' Moat Score too high?
DiaMedica Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. DiaMedica Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, DiaMedica Therapeutics ranks #344 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Moat Score compare to BCYC and RZLT?
According to the Biotechnology industry distribution chart, DiaMedica Therapeutics ranks #344 out of 1405 companies for Moat Score. This places DiaMedica Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. DiaMedica Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DiaMedica Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DiaMedica Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Moat Score is 3 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score

Get the complete analysis for DMAC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.38
Price